BioCentury | Sep 21, 2018
Financial News

DePinho's STAT3 company Tvardi raises $9M series A

...Tvardi to complete Phase I testing of TTI-101 and IND-enabling studies of a second compound, TTI-102...
...I study of IV TTI-101 for cachexia next year and hopes to begin studies of TTI-102...
...Therapeutics Inc. University of Texas MD Anderson Cancer Center Signal transducer and activator of transcription 3 (STAT3) Ronald DePinho TTI-101 TTI-102...
BioCentury | Sep 20, 2018
Financial News

DePinho's STAT3 company Tvardi raises $9M series A

...Tvardi to complete Phase I testing of TTI-101 and IND-enabling studies of a second compound, TTI-102...
...I study of IV TTI-101 for cachexia next year and hopes to begin studies of TTI-102...
...Ltd. Tvardi Therapeutics Inc. University of Texas MD Anderson Cancer Center Signal transducer and activator of transcription 3 (STAT3) TTI-101 TTI-102...
Items per page:
1 - 2 of 2